Rare diseases
Investigational molecules
Locations
703 conditions with trials, the busiest first
3 898 trials across Europe, recruiting first
Study on ANV600 and Pembrolizumab for Patients with Advanced Solid Tumors
BelgiumStudy of Debio 4228 for Patients with Advanced or Metastatic Prostate Cancer
BelgiumStudy on the Safety of ARV-471 and Everolimus for Patients with Advanced or Metastatic ER+, HER2- Breast Cancer
SpainStudy Comparing Zimberelimab and Domvanalimab with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Untreated Metastatic Non-Small Cell Lung Cancer
AustriaStudy on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer
AustriaStudy of Pembrolizumab for Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma or Primary Mediastinal Large B-cell Lymphoma
CzechiaStudy on Acalabrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients Without del(17p) or TP53 Mutation
AustriaStudy on Pausing Treatment with Pembrolizumab and Axitinib in Patients with Metastatic Kidney Cancer at Good or Intermediate Risk
FranceStudy of Encorafenib, Cetuximab, and Pembrolizumab for Patients with Untreated BRAF V600E-Mutant Metastatic Colorectal Cancer
BelgiumStudy on JAB-21822 for Adults with Advanced Solid Tumors with KRAS G12C Mutation
SpainStudy of Tucatinib and Ado-Trastuzumab Emtansine for Patients with Advanced HER2+ Breast Cancer
BelgiumStudy on the Safety and Effectiveness of Ivosidenib or Enasidenib with Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia with IDH1 or IDH2 Mutations
FranceThe therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
